Rosen Law Firm Investigates Immutep Securities Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IMMP?
Source: Globenewswire
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential issuance of materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On March 13, 2026, Immutep's stock price plummeted by $2.28 per ADR, or 82.6%, closing at $0.48, following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate without any upfront fees through a contingency fee arrangement, thereby reducing financial burdens on investors.
- Firm's Strength: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong expertise and track record in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.385
Low
12.00
Averages
12.00
High
12.00
Current: 0.385
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Immutep Securities Claims
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential issuance of materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On March 13, 2026, Immutep's stock price plummeted by $2.28 per ADR, or 82.6%, closing at $0.48, following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate without any upfront fees through a contingency fee arrangement, thereby reducing financial burdens on investors.
- Firm's Strength: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong expertise and track record in this field.
See More
Investigation into Immutep Limited for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Immutep Limited investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns over corporate governance.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial based on the Independent Data Monitoring Committee's recommendation, indicating that the drug's efficacy in non-small cell lung cancer patients did not meet expectations, which may impact the company's future R&D direction.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price fell by 82.44% to close at $0.48 per ADR, reflecting extreme pessimism in the market regarding the company's outlook.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, exacerbating investor concerns about corporate governance and financial health, potentially affecting its reputation and ability to raise capital in the market.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Ltd.
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, indicating significant legal risks for the company.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on recommendations from the Independent Data Monitoring Committee following an interim futility analysis, which has severely impacted investor confidence.
- Stock Price Plunge: Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action to recover investor losses, allowing participation without any out-of-pocket fees, demonstrating the firm's commitment to protecting investor rights.
See More
Immutep Faces Securities Claims Investigation
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential misleading business information issued to investors, which may lead to significant securities claims against the company.
- Stock Price Plunge: Following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study on March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, allowing affected shareholders to participate without any upfront fees, which may encourage broader participation from impacted investors.
- Firm's Reputation: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Immutep's TACTI-004 Trial Halted After Futility Analysis
- Trial Progress vs. Outcome: On January 30, 2026, Immutep's 6-K filing stated that the futility analysis for the TACTI-004 trial was 'on track,' but just six weeks later, the Independent Data Monitoring Committee (IDMC) recommended halting the trial, indicating the drug was unlikely to meet efficacy endpoints, resulting in an 80-90% stock price collapse in a single session.
- Investor Loss Alert: Shareholders are urged to act, particularly those who suffered losses on IMMP stock due to the trial's failure to meet primary efficacy endpoints, highlighting the potential for significant financial repercussions and the necessity for legal action.
- Lack of Transparency: Immutep made no public disclosures between the January 30 filing and the March 13 announcement regarding any changes in the trial's outlook, creating a stark information asymmetry that exacerbated investor disappointment and undermined market confidence.
- Key Asset Risk: TACTI-004 represents Immutep's lead oncology asset, and its failure not only impacts the company's market performance but may also have long-term negative implications for future R&D investments and shareholder trust.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Ltd.
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) due to allegations of materially misleading business information, highlighting serious concerns regarding the company's transparency.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for non-small cell lung cancer based on recommendations from the Independent Data Monitoring Committee, leading to a significant decline in investor confidence.
- Stock Price Collapse: Following this announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.28, or 82.6%, closing at $0.48, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action for affected investors, promising compensation without any upfront fees, demonstrating a commitment to protecting investor rights and interests.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential issuance of materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On March 13, 2026, Immutep's stock price plummeted by $2.28 per ADR, or 82.6%, closing at $0.48, following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate without any upfront fees through a contingency fee arrangement, thereby reducing financial burdens on investors.
- Firm's Strength: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong expertise and track record in this field.
See More
Investigation into Immutep Limited for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Immutep Limited investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns over corporate governance.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial based on the Independent Data Monitoring Committee's recommendation, indicating that the drug's efficacy in non-small cell lung cancer patients did not meet expectations, which may impact the company's future R&D direction.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price fell by 82.44% to close at $0.48 per ADR, reflecting extreme pessimism in the market regarding the company's outlook.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, exacerbating investor concerns about corporate governance and financial health, potentially affecting its reputation and ability to raise capital in the market.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Ltd.
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, indicating significant legal risks for the company.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on recommendations from the Independent Data Monitoring Committee following an interim futility analysis, which has severely impacted investor confidence.
- Stock Price Plunge: Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action to recover investor losses, allowing participation without any out-of-pocket fees, demonstrating the firm's commitment to protecting investor rights.
See More
Immutep Faces Securities Claims Investigation
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential misleading business information issued to investors, which may lead to significant securities claims against the company.
- Stock Price Plunge: Following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study on March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, allowing affected shareholders to participate without any upfront fees, which may encourage broader participation from impacted investors.
- Firm's Reputation: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Immutep's TACTI-004 Trial Halted After Futility Analysis
- Trial Progress vs. Outcome: On January 30, 2026, Immutep's 6-K filing stated that the futility analysis for the TACTI-004 trial was 'on track,' but just six weeks later, the Independent Data Monitoring Committee (IDMC) recommended halting the trial, indicating the drug was unlikely to meet efficacy endpoints, resulting in an 80-90% stock price collapse in a single session.
- Investor Loss Alert: Shareholders are urged to act, particularly those who suffered losses on IMMP stock due to the trial's failure to meet primary efficacy endpoints, highlighting the potential for significant financial repercussions and the necessity for legal action.
- Lack of Transparency: Immutep made no public disclosures between the January 30 filing and the March 13 announcement regarding any changes in the trial's outlook, creating a stark information asymmetry that exacerbated investor disappointment and undermined market confidence.
- Key Asset Risk: TACTI-004 represents Immutep's lead oncology asset, and its failure not only impacts the company's market performance but may also have long-term negative implications for future R&D investments and shareholder trust.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Ltd.
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) due to allegations of materially misleading business information, highlighting serious concerns regarding the company's transparency.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for non-small cell lung cancer based on recommendations from the Independent Data Monitoring Committee, leading to a significant decline in investor confidence.
- Stock Price Collapse: Following this announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.28, or 82.6%, closing at $0.48, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action for affected investors, promising compensation without any upfront fees, demonstrating a commitment to protecting investor rights and interests.
See More
